Cytotherapy Editorial Board

Cytotherapy CoverMission Statement

Position Cytotherapy as the premier cell and gene therapy translation journal, by developing the Cytotherapy brand as the "first submission choice" for all cell and gene therapy translation manuscripts.

Aims and Scope

Cytotherapy, the official journal of the ISCT, publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. Studies evaluating the potency of experimental cell and gene therapies in clinically relevant animal models of disease and describing important advances in cell/gene-based product manufacturing and validation are welcomed. Results of clinical studies evaluating the safety and efficacy of cell and gene therapies in early and late phase trails are also of interest. In addition to short reports and full-length articles, the journal also accepts editorials addressing emerging trends and potential controversies in the field, and review articles summarizing bodies of work that have made lasting impacts in the field.

The journal's scope includes research in the following:

  • Stem cell processing and transplantation
  • Cell-based therapies of malignant and non-malignant blood diseases
  • Cancer
  • Stem cell plasticity
  • Autoimmune diseases
  • Immunotherapy
  • Congenital disorders
  • Novel molecular therapies
  • Gene therapy
  • Microvesicle biology and therapeutic application

Readership and Target Group

Cytotherapy provides essential reading for scientists, physicians, technicians and regulatory experts involved in cell processing and therapy. It is a vital resource for hematologists, oncologists and immunologists, and the growing number of physicians from many disciplines involved in tissue repair and stem cell research, cytokine investigators, cancer biologists and biotherapists.


Cytotherapy, Cytokine, Translational Research, Stem Cells, Cellular Therapies, Vaccines, Gene Therapy, Immunotherapy, Tissue Engineering, Blood and Bone Marrow, T cells.

Submission Details

Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt whether the manuscript is accepted, requires revision or is rejected. All manuscripts will be published within five months from the date of acceptance. Contributors, submit manuscripts here.

Journal Leadership

Donald_Phinney.jpgSenior Editor

Donald G. Phinney, PhD

The Scripps Research Institute
United States

Patrick_Hanley_2017_cropped.jpgCommissioning Editor

Patrick J. Hanley, PhD

Children's National Hospital
United States

Associate Editors

Oscar Lee, MD, PhD
National Yang-Ming University

Luis A. Ortiz, MD
University of Pittsburgh

United States
Anna Pasetto, PhD
Karolinska Institutet

Qasim A. Rafiq, PhD
University College London

United Kingdom
Sowmya Viswanathan, PhD
University Health Network


Editorial Board

The editors are supported by an international editorial board made up of over 35 eminent academics in the field.

Ande Nichols
Publisher, Cytotherapy